Abstract
Available commercially as Allegra D®, fexofendine has been the drug of first choice for the symptomatic treatment of allergic manifestations, as a non-sedating antihistamine agent. It is an active and chiral metabolite of terfenadine, a drug whose production and trading was suspended due to adverse events. The aim of this project is to develop and to validate a method to be further applie…